To evaluate the Safety and medicinal effectiveness of Unani formulations Damavi in SÅ«â?? al Qinya(Anaemia)

Clinical Validation of a Unani Pharmocopoeial Formulation â?? Damavi in SÅ«â?? al-Qinya(Anaemia)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/10/006273

Enrollment

200

Registered

2015-10-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified Health Condition 2: null- SÅ«â?? al-Qinya(Anaemia)

Interventions

Intervention1: Tablet Damavi: 2 Tablets ,once daily, orally to be taken with water after meals Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: •SÅ«â?? al-Qinya(anaemia) with Haemoglobin level 8-12 g/dL in men and 8-11 g/dL in women with or without any of the following signs and symptoms: ï?§ ShuhÅ«b (Pallor) ï?§ NaqÄ?hat (Weakness) ï?§ Iâ??yÄ?â?? (Fatigue) ï?§ â??Usr al-Tanaffus (Dyspnoea)

Exclusion criteria

Exclusion criteria: 1. Patients with severe anaemia (Hb 2. Patients having anaemia with any associated severe complications 3. Patients having occult blood positive on stool examination. 4. Patients with sickle cell anaemia, aplastic anaemia, sideroblasticanaemia, anaemia due to malignancies, thalassaemia, hereditary spherocytosis, and lead poisoning. 5. Patients with chronic diseases requiring long-term treatment such as diabetes mellitus, tuberculosis, HIV infection, lukaemia, endocrine disorders, haemorrhagic diathesis (hemophilia, ITP), bleeding piles, menorragia, metrorrhagia or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data. 6. Patients with concurrent serious hepatic, cardiac, renal or pulmonary dysfunction. 7. Pregnant and lactating women 8. H/o addiction (alcohol, drugs) 9. H/o Hypersensitivity to the study drug or any of its ingredients.

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of SÅ«â?? al-Qinya(Anaemia)Timepoint: 8 weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDR PRADEEP KUMAR

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026